The EVP – CBO – GC & Secretary of Karyopharm Therapeutics Inc. (KPTI), Christopher Primiano Sold 2,500 Shares of the Company; Uss Investment Management LTD Has Decreased Its Cae (CAE) Holding

The EVP – CBO – GC & Secretary of Karyopharm Therapeutics Inc, Christopher Primiano has made a sudden sale in the Massachusetts-based company that is amounting to $37,527 USD. As disclosed in the SEC form filed on February 20, 2018, Christopher unloaded 2,500 shares based on an average stock price per share of $15.0. In the last month, he also unloaded 1,500 shares worth total $19,500 USD. Christopher Primiano now has rights to 7,381 shares or 0.01% of Karyopharm Therapeutics Inc’s market cap.

Uss Investment Management Ltd decreased Cae Inc (CAE) stake by 13.17% reported in 2017Q3 SEC filing. Uss Investment Management Ltd sold 414,010 shares as Cae Inc (CAE)’s stock rose 0.90%. The Uss Investment Management Ltd holds 2.73 million shares with $47.94M value, down from 3.14 million last quarter. Cae Inc now has $4.87 billion valuation. The stock decreased 1.81% or $0.34 during the last trading session, reaching $18.43. About 272,872 shares traded or 1.90% up from the average. CAE Inc. (NYSE:CAE) has risen 26.75% since February 20, 2017 and is uptrending. It has outperformed by 10.05% the S&P500.

Among 9 analysts covering CAE Inc. (NYSE:CAE), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. CAE Inc. had 17 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was upgraded by Zacks to “Sell” on Friday, August 14. The company was upgraded on Friday, May 27 by Macquarie Research. The firm earned “Outperform” rating on Wednesday, August 30 by BMO Capital Markets. The stock of CAE Inc. (NYSE:CAE) has “Outperform” rating given on Friday, February 12 by BMO Capital Markets. The stock of CAE Inc. (NYSE:CAE) earned “Hold” rating by Zacks on Tuesday, September 1. The rating was downgraded by BMO Capital Markets to “Market Perform” on Friday, May 20. On Monday, January 4 the stock rating was upgraded by IBC to “Outperform”. The stock of CAE Inc. (NYSE:CAE) earned “Hold” rating by TD Securities on Thursday, June 1. The company was upgraded on Monday, February 12 by RBC Capital Markets. The firm earned “Sell” rating on Tuesday, September 22 by Zacks.

Uss Investment Management Ltd increased Alliance Data Systems Corp (NYSE:ADS) stake by 40,000 shares to 546,000 valued at $120.94M in 2017Q3. It also upped Consolidated Edison Inc (NYSE:ED) stake by 9,600 shares and now owns 89,144 shares. Xylem Inc (NYSE:XYL) was raised too.

Investors sentiment increased to 1.29 in 2017 Q3. Its up 0.14, from 1.15 in 2017Q2. It improved, as 9 investors sold CAE shares while 47 reduced holdings. 20 funds opened positions while 52 raised stakes. 132.48 million shares or 2.20% less from 135.47 million shares in 2017Q2 were reported. Cibc Asset Mngmt Inc reported 107,057 shares stake. Geode Cap Mgmt holds 0% or 142,516 shares in its portfolio. Aqr Mngmt Ltd Liability has invested 0.01% in CAE Inc. (NYSE:CAE). Commerzbank Aktiengesellschaft Fi holds 0.01% of its portfolio in CAE Inc. (NYSE:CAE) for 31,701 shares. Moreover, Lincluden has 0.07% invested in CAE Inc. (NYSE:CAE). Thompson Davis Company holds 0.09% or 2,825 shares. Dekabank Deutsche Girozentrale holds 31,388 shares. Jpmorgan Chase invested in 0% or 1.06M shares. Amp Cap Investors owns 155,585 shares for 0.02% of their portfolio. Credit Suisse Ag reported 0.01% in CAE Inc. (NYSE:CAE). Comml Bank Of Nova Scotia reported 1.19 million shares stake. Manufacturers Life Ins Company The has invested 0.04% in CAE Inc. (NYSE:CAE). Prtnrs Ltd Company reported 0.03% stake. Advsrs Asset Management has invested 0.01% in CAE Inc. (NYSE:CAE). Canada Pension Plan Investment Board owns 519,725 shares or 0.02% of their US portfolio.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $24.36’s average target is 66.96% above currents $14.59 stock price. Karyopharm Therapeutics Inc. had 28 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm has “Buy” rating given on Thursday, January 11 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, September 8 by H.C. Wainwright. H.C. Wainwright reinitiated the shares of KPTI in report on Wednesday, November 15 with “Buy” rating. The firm earned “Buy” rating on Tuesday, December 22 by Canaccord Genuity. The firm has “Buy” rating given on Wednesday, August 12 by MLV. The firm has “Overweight” rating given on Monday, March 14 by JP Morgan. The firm has “Buy” rating given on Monday, October 16 by RBC Capital Markets. The firm has “Buy” rating given on Friday, June 23 by Cantor Fitzgerald. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Tuesday, December 12 by H.C. Wainwright.

Investors sentiment increased to 2.5 in Q3 2017. Its up 0.94, from 1.56 in 2017Q2. It is positive, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported. Susquehanna Group Inc Ltd Liability Partnership accumulated 56,014 shares. Tekla Capital Mngmt Ltd Limited Liability Company accumulated 756,679 shares. Fmr Ltd Company has invested 0.01% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). D E Shaw stated it has 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Millennium Management Ltd accumulated 0.01% or 370,916 shares. Automobile Association stated it has 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Thomas J Herzfeld Advsr owns 0.02% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 4,868 shares. Iguana Healthcare Mngmt Ltd Company invested 2.45% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Moreover, Raymond James has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Proshare Advsr Ltd Liability Corporation reported 28,871 shares. Group invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Mutual Of America Management Llc owns 0.03% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 154,449 shares. Schwab Charles Inv Mgmt Inc holds 0% or 140,360 shares in its portfolio. Baker Bros Advsrs L P reported 216,990 shares. Blackrock holds 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 3.04 million shares.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $722.69 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on March, 15. They expect $-0.58 EPS, up 10.77% or $0.07 from last year’s $-0.65 per share. After $-0.65 actual EPS reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -10.77% EPS growth.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: